Global Beta-Adrenoceptor Agonists (β-agonists) Market, By Type (β1 Agonists, β2 Agonists, Others), Drugs (Epinephrine, Norepinephrine, Dopamine, Dobutamine, Isoproterenol, Others) Diseases (Asthma, Anaphylactic Shock, Cardiogenic Shock, Cardiac Arrest, Severe Hypotension, Septic Shock, Acute Heart Failure, Acute Renal Failure, Bradycardia and Atrioventricular Block Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Beta-Adrenoceptor Agonists (β-agonists) Market Analysis and Size
The global beta-adrenoceptor agonists (β-agonists) market is expected to witness significant growth during the forecast period. As per the reports of the WHO, it is projected that 1.13 billion people globally have hypertension, almost two-thirds who are living in low- and middle-income countries or 2015 it is projected that in 1 in 4 men and 1 in 5 women had hypertension. Growing company initiatives to provide better treatment and rising investment by biotechnology and pharmaceutical industries in R&D boost the global beta-adrenoceptor agonists (β-agonists) market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global beta-adrenoceptor agonists (β-agonists) market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Beta-adrenoceptor agonists (β-agonists) bind to the β-receptors on the smooth muscle tissues and cardiac tissues. They also have important actions in other tissues, especially bronchial smooth muscle, the liver, and kidneys. Beta-adrenoceptors usually bind to norepinephrine that is released by the sympathetic adrenergic nerves, and to circulating epinephrine. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Beta-Adrenoceptor Agonists (β-agonists) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (β1 Agonists, β2 Agonists, Others), Drugs (Epinephrine, Norepinephrine, Dopamine, Dobutamine, Isoproterenol, Others) Diseases (Asthma, Anaphylactic Shock, Cardiogenic Shock, Cardiac Arrest, Severe Hypotension, Septic Shock, Acute Heart Failure, Acute Renal Failure, Bradycardia and Atrioventricular Block Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Amneal Pharmaceuticals LLC (U.K.), Eisai Co., Ltd (Japan)
|
|
Market Opportunities
|
|
Global Beta-Adrenoceptor Agonists (β-agonists) Market Dynamics
Drivers
- Anti-Inflammatory effects of antagonists
In several diseases such as asthma, beta-adrenoceptor agonists play a synthetic role by secreting inflammatory mediators. ASM may produce multiple inflammatory mediators such as prostanoids, cyto- and chemokines, thus perpetuating and amplifying the inflammatory process within the airway wall. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs are expected to boost market growth. The segment is expected to boost the global market as most of the products are available in capsule form and tablet form and it is a very feasible route of administration.
Opportunities
- Patent Expiration Encourages New Launches
The patent expiration of old companies can create better opportunities for the several new market players. The adoption of numerous combination therapies is a significant factor that contributes to the growth of the capecitabine market. Additionally, R&D fundings are an add-on to the market.
- Rising Healthcare Awareness
Several awareness among patients as well as healthcare providers about the incidence of types of cancer is on the rise. Patients and doctors are now more majorly participating in learning about the therapies that are available for treating these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.
Restraints/Challenges
- Increasing Cost Of Treatments
The huge expenditure that is required for the treatment methods hamper the market growth. Many of the treatments involved in this disease demand high cost and thus at times gets difficult for many people, particularly the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global beta-adrenoceptor agonists (β-agonists) market over a forecast period.
This global beta-adrenoceptor agonists (β-agonists) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global beta-adrenoceptor agonists (β-agonists) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Beta-Adrenoceptor Agonists (β-agonists) Market Scope
The global beta-adrenoceptor agonists (β-agonists) market is segmented on the basis of type, drug, diseases, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- β1 Agonists
- β2 Agonists
- Others
Drug
- Epinephrine
- Norepinephrine
- Dopamine
- Dobutamine
- Isoproterenol
- Others
Diseases
- Asthma
- Anaphylactic Shock
- Cardiogenic Shock
- Cardiac Arrest
- Severe Hypotension
- Septic Shock
- Acute Heart Failure
- Acute Renal Failure
- Bradycardia
- Atrioventricular Block
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Beta-Adrenoceptor Agonists (β-agonists) Market Regional Analysis/Insights
The global beta-adrenoceptor agonists (β-agonists) market is analysed and market size insights and trends are provided by type, diseaes, drug, distribution channel and end-user as referenced above.
The major countries covered in the global beta-adrenoceptor agonists (β-agonists) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to rising healthcare infrastructure and rising government and pharmaceutical initiatives for the better treatment.
North America dominates the market due to the increased consumption of cardiovascular drugs for the treatment of cardiac diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Beta-Adrenoceptor Agonists (β-agonists) Market Share Analysis
The global beta-adrenoceptor agonists (β-agonists) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global beta-adrenoceptor agonists (β-agonists) market.
Key players operating in the global beta-adrenoceptor agonists (β-agonists) market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Amneal Pharmaceuticals LLC (U.K.)
- Eisai Co., Ltd (Japan)
SKU-